GSK’s Nucala was first approved in 2015 for the treatment of severe eosinophilic asthma. Credit: GSK.

GlaxoSmithKline (GSK) has secured a positive recommendation from a European Medicines Agency (EMA) panel for its Nucala (mepolizumab) medication.

The drug is designed for self-administration using a pre-filled pen or safety syringe.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

First approved in 2015 for the treatment of severe eosinophilic asthma, Nucala is a monoclonal antibody (mAb) designed to target IL-5 and decrease blood eosinophils. It is intended for treating conditions that are driven by eosinophil-caused inflammation.

Assessed in 16 clinical trials across various eosinophilic indications, Nucala has secured approval as an add-on maintenance therapy for eosinophilic asthma in more than 20 markets, including the US and Europe. It has received approval as an add-on maintenance treatment for eosinophilic granulomatosis with polyangiitis (EGPA) patients in countries such as the US, Japan and Canada.

Nucala 100mg solution in pre-filled pen and pre-filled syringe are suitable for adults and adolescents.

The positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) is based on results from two open-label, single-arm, Phase IIIa clinical trials. These studies investigated the real-world use of the administration options in clinic and at-home by severe eosinophilic asthma patients or their caregivers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Patients in both trials were able to successfully self-administer treatment with the pre-filled pen, as well as pre-filled safety syringe following appropriate training.

The trials found that most patients preferred at-home options compared to in-clinic administration.

In addition, an open-label, parallel-group, single-dose pharmacokinetic (PK) and pharmacodynamic (PD) study validated that the administration options were comparable to the lyophilised version, noted GSK.